ORG – Talk Bio

Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law

9 hours ago talkbio0Tagged Acquisition, Antitrust, bidding war, Metsera, Novo Nordisk, Obesity, Pfizer, Twice a day, Unsolicited Adverse Event, Weight-Loss Agents

Novo Nordisk; Metsera; Pfizer; acquisition; bidding war; obesity; antitrust; unsolicited bid; weight-loss drugs

Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

9 hours ago talkbio0Tagged earnings, eli lilly, exophthalmos producing substance, full-year guidance, Mounjaro, pharmaceutical innovation, Q3, revenue growth, Weight-Loss Agents, Zepbound

Eli Lilly; Q2 2025 earnings; Q3 2025 earnings; Mounjaro; Zepbound; weight-loss drugs; revenue growth; EPS; full-year guidance; pharmaceutical innovation

Takeda Makes Pipeline Cuts and Faces Softer Q2 Sales Due to Generic Competition

9 hours ago talkbio0Tagged Drug Development, Generic competition, impairment charges, Late stage, Operating, pipeline, Q2 sales, restructuring, Takeda, Vyvanse

Takeda; pipeline cuts; generic competition; Q2 sales; Vyvanse; restructuring; operating profit; impairment charges; drug development; late-stage pipeline

Roche Signs $1B Licensing Deal with Qyuns Therapeutics for Preclinical COPD Bispecific Antibody

9 hours ago talkbio0Tagged Antibodies, Bispecific, biobucks, China, COPD, IL33 protein, human, Preclinical, Qyuns Therapeutics, Respiration Disorders, Roche (company), TSLP gene

Roche; Qyuns Therapeutics; bispecific antibody; COPD; preclinical; TSLP; IL-33; China biotech; biobucks; respiratory disease

Ventus Therapeutics Continues Phase 2a Trial of VENT-02 NLRP3 Inhibitor in Parkinson’s Disease; No Indication of Program Halt

9 hours ago talkbio0Tagged Biological Markers, Clinical Development, Neuroinflammation, NLRP3 inhibitor, Parkinson 's disease, Phase 2a Trial, VENT-02, Ventus Therapeutics

Ventus Therapeutics; VENT-02; NLRP3 inhibitor; Phase 2a trial; Parkinson’s disease; clinical development; neuroinflammation; biomarkers

FDA Reduces Regulatory Red Tape for Biosimilars

9 hours ago talkbio0Tagged approvals, Biosimilars, faster, Financial cost, regulatory changes, United States Food and Drug Administration

FDA; biosimilars; regulatory changes; cost reduction; faster approvals

United Imaging Healthcare Q3 2025 Results: Overseas Revenue Up 42% YoY

12 hours ago talkbio0Tagged Global Expansion, Investments, Market, Medical Imaging, overseas, Q3, revenue growth, United Imaging Healthcare

United Imaging Healthcare; Q3 2025 results; overseas revenue growth; medical imaging; emerging markets; R&D investment; global expansion

Cytek Biosciences Deepens Commitment to Expanding Access to Flow Cytometry

12 hours ago talkbio0Tagged Amsterdam facility, Awards, cell analysis, Collaboration, Cytek Biosciences, European (ethnic group), expansion, Flow Cytometry, FSP, Instrument - device, ISAC, Research Projects, R-Series, Spectrum Profiling

Cytek Biosciences; flow cytometry; access expansion; ISAC collaboration; instrument awards; research grants; Full Spectrum Profiling (FSP); European expansion; Amsterdam facility; cell analysis

GSK Trims Pipeline and Upgrades Guidance in Emma Walmsley’s Last Earnings Report

1 day ago talkbio0Tagged dividend, earnings, Emma Walmsley, guidance upgrade, Medical Specialities, operating profit, pipeline reduction, R&D, SmithKline Beecham

GSK; pipeline reduction; earnings; Emma Walmsley; Q3 2025; guidance upgrade; Specialty Medicines; operating profit; dividend; R&D progress

Eli Lilly and Nvidia to Build Pharma’s Largest AI Supercomputer for Drug Discovery

1 day ago talkbio0Tagged Artificial Intelligence, biomedical foundation models, Blackwell Ultra GPU, Clinical Trials, Drug Discovery, Drug Industry, eli lilly, high-performance computing, NVIDIA, supercomputer

Eli Lilly; Nvidia; supercomputer; AI; drug discovery; Blackwell Ultra GPU; clinical trials; biomedical foundation models; pharmaceutical industry; high-performance computing